Khosla Ventures

KV’s investment thesis centers on technology‑driven disruption of large, addressable markets. The firm seeks “unfair advantages” such as proprietary IP, breakthrough science, novel business models, or unique partnerships, and prefers founders with deep technical expertise and conviction. Core sectors include Consumer, Enterprise, Fintech, Frontier (space, quantum, deep tech), MedTech & Diagnostics, Digital Health, Therapeutics, and Sustainability/Climate. AI is highlighted as a transformative force across all domains. Geography is global, with a strong U.S. base but investments in India, New Zealand, and other regions. KV targets early‑stage opportunities where a non‑consensus idea can become a category leader, backing both pure science experiments (Seed Fund) and later‑stage scaling (Main Fund). The firm avoids incremental “me‑too” products, business plans that depend on copying incumbents, and pitches that rely solely on long‑term financial projections without concrete technical risk mitigation. Its core belief is that ambitious, technically differentiated startups can reinvent societal goods and generate outsized value, and KV aims to be early, bold, and impactful by backing such “black‑swan” potential.

KV evaluates investments differently across its Seed and Main funds. For Seed, the firm looks for a “crazy idea” with a plausible technical path and a clear plan to reduce key risks cheaply. Weight is placed on (a) deep technical insight and risk decomposition, (b) founder quality and the ability to “engineer the gene pool,” and (c) a billion‑dollar market opportunity with a defensible unfair advantage (IP, business‑model innovation). They explicitly discount long‑range financial forecasts, vanity user metrics, and me‑too product copies. Deal‑breakers include lack of clear risk‑reduction milestones, teams seeking only capital without willingness to collaborate, and pitches that rely on copying incumbents. For the Main Fund, KV expects more risk to be retired, so market size, financials, go‑to‑market strategy, and team completeness gain weight, though technology risk remains significant. Traction is considered but is secondary at Seed. Overall, team‑tech insight and market potential dominate the decision matrix.

• Opendoor
  Reinventing the inefficient real-estate market with a technology-driven operating model. Khosla invested in the 2014 Seed round.
• FormularyLead
  AI-based infrastructure for private-market fund administration. Khosla led the $4.6M seed (Jan 2026).
• Peripheral LabsLead
  Advanced sensing and vision tech for autonomous-grade sports experiences. Khosla led the $3.6M seed (Dec 2025).
• Impossible Foods
  Food-tech moonshot with massive environmental upside, consistent with KV's sustainability and deep-tech focus.
• Guardant Health
  Precision oncology liquid-biopsy platform that transforms healthcare diagnostics, a classic KV health-tech investment.
• QuantumScape
  Solid-state battery technology for EVs, representing KV's deep-tech energy-storage bet.
• Nutanix
  Category-creating enterprise infrastructure backed pre-revenue, illustrating KV's comfort with high technical risk before metrics appear.
• Ultima Genomics
  Platform that dramatically lowers genomics costs, fitting KV's deep-tech and large-impact healthcare thesis.

• 
  OrbiMed

  Guardant Health
• 
  Pear VC

  Guardant Health